Financing ·
Grace Therapeutics reported a net loss of $15.8 million for the quarter ended June 30, 2026, driven by a $13.5 million…
GRCEGrace Therapeutics, Inc.
Grace Therapeutics reported a net loss of $15.8 million for the quarter ended June 30, 2026, driven by a $13.5 million impairment of in-process research and development assets related to deprioritized candidates GTx-101 and GTx-102. The company announced a $10 million private placement financing to support manufacturing and regulatory work for its lead asset, GTx-104. Management provided an update on the New Drug Application resubmission strategy following a previous Complete Response Letter from the FDA, outlining a dual-source manufacturing approach involving remediation at the current contract manufacturer and technology transfer to a second U.S.-based facility. Cash and cash equivalents stood at $22.2 million as of August 11, 2026, extending the cash runway through the end of calendar 2028. Grace Therapeutics is a late-stage biopharmaceutical company developing novel drug delivery technologies for rare diseases.